Track the UFP TECHNOLOGIES INC stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, UFP TECHNOLOGIES INC has logged 3 public disclosures. Market capitalisation: €1.7bn. The latest transaction was reported on 11 May 2021 (Acquisition). Among the most active insiders: CROTEAU DANIEL C. The full history is accessible without an account.
Analysts rate UFP TECHNOLOGIES INC Buy (bullish), based on 2 analysts. Average price target: US$324.50.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
UFP Technologies Inc. (NASDAQ: UFPT) is a U.S.-based contract development and manufacturing company focused on single-use and single-patient medical devices. Listed on the NASDAQ market in the United States, the company serves a broad set of medical-device customers, especially in minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its business model is built around custom-engineered, high-complexity solutions that are embedded early in the customer value chain and require strong design, quality, and manufacturing capabilities. ([ufpt.com](https://ufpt.com/investors/?utm_source=openai)) The company traces its roots back to 1963 and is headquartered in Newburyport, Massachusetts, United States. Over time, UFP Technologies evolved from a materials- and foam-processing heritage into a medical-focused industrial platform. That strategic shift has helped the company build a niche position in a market where regulatory rigor, validation requirements, and supply-chain reliability create meaningful barriers to entry. Its capabilities span engineering, prototyping, tooling, assembly, and commercial-scale production. ([ufpt.com](https://ufpt.com/about-us/?utm_source=openai)) From a competitive standpoint, UFP Technologies is positioned as a specialized outsourcing partner rather than a broad-based manufacturer. It competes by offering customization, technical expertise, manufacturing consistency, and the ability to support long-cycle medical programs from concept through ramp-up and full-scale production. That positioning is attractive for medical OEMs seeking partners who can help them accelerate innovation while preserving quality and supply continuity. In practice, the company benefits from the structural trend toward outsourcing of more complex medical components and assemblies. ([ufpt.com](https://ufpt.com/investors/?utm_source=openai)) Its core product and service lines include medical-device components, sterile packaging, and other highly engineered custom products. UFP Technologies has also emphasized technology platforms such as thermoforming, thermoplastic molding, tight-tolerance films, and solutions used in implantable applications. In July 2025, the company announced the acquisitions of UNIPEC and TPI, moves that expanded its capabilities in tight-tolerance film components and thermoplastic molding for the medical device market. Management said these deals further strengthen the company’s platform in demanding implantable and battery-shielding applications. ([ufpt.com](https://ufpt.com/news/ufp-technologies-acquires-unipec-and-tpi-to-expand-film-and-thermoplastic-molding-capabilities/?utm_source=openai)) Geographically, the business is anchored in the United States, with headquarters in Massachusetts and an operating footprint that has expanded through acquisitions, including facilities in the Dominican Republic. Recent disclosures show continued momentum: 2025 sales increased materially, and first-quarter 2026 results also reflected higher revenue and earnings, supported by acquisition contributions and organic growth in medical end markets. Management has indicated that recent acquisitions are performing well and that integration is essentially complete, while the company continues to evaluate new acquisition opportunities. For investors, UFPT represents a specialized NASDAQ-listed medtech manufacturing story with growth driven by outsourcing, engineering depth, and disciplined M&A. ([ufpt.com](https://ufpt.com/news/ufp-technologies-announces-strong-q1-results/?utm_source=openai))